Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects. For further information on the company, please visit www.destinypharma.com
Location: United Kingdom, England, Brighton
Employees: 11-50
Total raised: $4.73M
Founded date: 1997
Investors 4
| Date | Name | Website |
| 17.06.2024 | Angel CoFu... | acfinvesto... |
| - | Bioscience... | bioscience... |
| - | Downing Ve... | downing.co... |
| - | Juno Capit... | junocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.08.2014 | - | $4.73M | - |
Mentions in press and media 25
| Date | Title | Description |
| 06.05.2022 | With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB | Michel Vounatsos → Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive efficacy questions. The highl... |
| 17.12.2021 | Destiny Pharma : Grant of share options | Destiny Pharma plc ("Destiny Pharma" or the "Company") Grant of share options Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage biotechnology company focused on the development of novel medicines t... |
| 15.11.2021 | Destiny Pharma : Directorate Change | Destiny Pharma plc ("Destiny Pharma" or "the Company") Directorate change Brighton, United Kingdom - 15 November 2021- Destiny Pharma plc (AIM: DEST) a clinical stage biotechnology company focused on the development of n... |
| 04.11.2021 | SAB Member Prof. Gerding is Keynote at C.diff Conf | Destiny Pharma plc ("Destiny Pharma" or "the Company") Destiny Pharma's SAB Member Professor Dale Gerding is Keynote Speaker at C. diff.International Conference Brighton, United Kingdom - 4th November 2021 -Destiny Pharm... |
| 18.10.2021 | Destiny Pharma : Study gives strong support for potential of XF-73 | Destiny Pharma plc ("Destiny Pharma" or "the Company") Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus Strong support for potenti... |
| 09.09.2021 | Destiny Pharma : Interim results for six months ended 30 June 2021 | Destiny Pharma plc ('Destiny Pharma'or the 'Company') Interim results for the six months ended 30 June 2021 Primary endpoint met in XF-73 Phase 2b clinical trial Secondary endpoint analysis showed XF-73 exhibited a significant and sustained... |
| 09.07.2021 | Destiny Pharma : 09 July 2021 – XF-73 Phase 2b data to be presented at ECCMID | Destiny Pharma plc ('Destiny Pharma' or 'the Company') Successful XF-73 nasal gel Phase 2b study data to be presented at 2021 ECCMID Congress Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract Brighton, U... |
| 10.06.2021 | DESTINY PHARMA PLC Destiny Pharma : XF-73 data abstract to be presented at 2021 ECCMID | Destiny Pharma plc ('Destiny Pharma' or 'the Company') Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress · XF-73 met its primary end point with >99% nasal S. aureu... |
| 10.06.2021 | DESTINY PHARMA PLC Destiny Pharma : 10 June 2021 – XF-73 data abstract to be presented at 2021 ECCMID | Destiny Pharma plc ('Destiny Pharma' or 'the Company') Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress XF-73 met its primary end point with >99% nasal aureus red... |
| 19.05.2021 | Destiny Pharma : 19 May 2021 – Notice to Register for 2021 AGM | Destiny Pharma plc ('Destiny Pharma' or 'the Company') Notice to Register for 2021 AGM Brighton, United Kingdom - 19 May 2021 - Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of n... |
Show more